IN2015DN03751A - - Google Patents

Info

Publication number
IN2015DN03751A
IN2015DN03751A IN3751DEN2015A IN2015DN03751A IN 2015DN03751 A IN2015DN03751 A IN 2015DN03751A IN 3751DEN2015 A IN3751DEN2015 A IN 3751DEN2015A IN 2015DN03751 A IN2015DN03751 A IN 2015DN03751A
Authority
IN
India
Prior art keywords
substituted
pyrimidine
isothiazolo
monocyclic
organ
Prior art date
Application number
Other languages
English (en)
Inventor
Claire Louise Kulisa
Daniel Christopher Brookings
Daniel James Ford
Richard Jeremy Franklin
James Thomas Reuberson
Anant Ramrao Ghawalkar
Original Assignee
Ucb Biopharma Sprl
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl, Univ Leuven Kath filed Critical Ucb Biopharma Sprl
Publication of IN2015DN03751A publication Critical patent/IN2015DN03751A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/424Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IN3751DEN2015 2012-10-03 2013-10-02 IN2015DN03751A (th)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1217704.4A GB201217704D0 (en) 2012-10-03 2012-10-03 Therapeutic agents
PCT/EP2013/070600 WO2014053581A1 (en) 2012-10-03 2013-10-02 Therapeutically active oxazoline derivatives

Publications (1)

Publication Number Publication Date
IN2015DN03751A true IN2015DN03751A (th) 2015-10-02

Family

ID=47225621

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3751DEN2015 IN2015DN03751A (th) 2012-10-03 2013-10-02

Country Status (11)

Country Link
US (1) US9382263B2 (th)
EP (1) EP2903990B1 (th)
JP (1) JP6184501B2 (th)
CN (1) CN104936962B (th)
BR (1) BR112015007503A2 (th)
CA (1) CA2886265A1 (th)
ES (1) ES2639293T3 (th)
GB (1) GB201217704D0 (th)
IN (1) IN2015DN03751A (th)
RU (1) RU2656209C2 (th)
WO (1) WO2014053581A1 (th)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016081732A1 (en) 2014-11-19 2016-05-26 Memorial Sloan-Kettering Cancer Center Thienopyrimidines and uses thereof
AR104020A1 (es) * 2015-06-04 2017-06-21 Kura Oncology Inc Métodos y composiciones para inhibir la interacción de menina con proteínas mill
GB201517263D0 (en) 2015-09-30 2015-11-11 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
GB201521767D0 (en) 2015-12-10 2016-01-27 Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R&D Therapeutic agents
ES2947636T3 (es) 2016-03-16 2023-08-14 Kura Oncology Inc Derivados de tieno[2,3-d]pirimidina sustituida como inhibidores de menina-MLL y métodos de uso
WO2018175746A1 (en) 2017-03-24 2018-09-27 Kura Oncology, Inc. Methods for treating hematological malignancies and ewing's sarcoma
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
TW201920170A (zh) 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 經取代之menin-mll 抑制劑及使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001079203A1 (en) * 2000-04-17 2001-10-25 Basf Aktiengesellschaft Herbicidal 3-heterocyclic substituted benzisothiazole and benzisoxazole compounds
KR101139314B1 (ko) * 2003-08-29 2012-04-26 베르날리스(캠브리지)리미티드 피리미도티오펜 화합물
US20080200475A1 (en) * 2005-03-28 2008-08-21 Pfizer Inc. 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors
US20100063047A1 (en) * 2008-09-10 2010-03-11 Kalypsys, Inc. Aminopyrimidine inhibitors of histamine receptors for the treatment of disease
EP2405973B1 (en) 2009-03-13 2015-04-22 Katholieke Universiteit Leuven, K.U. Leuven R&D Thiazolopyrimidine modulators as immunosuppressive agents
US8993552B2 (en) * 2009-09-04 2015-03-31 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
GB201012889D0 (en) 2010-08-02 2010-09-15 Univ Leuven Kath Antiviral activity of novel bicyclic heterocycles
GB201015411D0 (en) * 2010-09-15 2010-10-27 Univ Leuven Kath Anti-cancer activity of novel bicyclic heterocycles
GB201114212D0 (en) * 2011-08-18 2011-10-05 Ucb Pharma Sa Therapeutic agents
GB201119401D0 (en) * 2011-11-10 2011-12-21 Ucb Pharma Sa Therapeutic agents

Also Published As

Publication number Publication date
ES2639293T3 (es) 2017-10-26
CN104936962A (zh) 2015-09-23
WO2014053581A1 (en) 2014-04-10
CA2886265A1 (en) 2014-04-10
JP6184501B2 (ja) 2017-08-23
JP2015531388A (ja) 2015-11-02
EP2903990A1 (en) 2015-08-12
RU2656209C2 (ru) 2018-06-01
US9382263B2 (en) 2016-07-05
CN104936962B (zh) 2017-02-22
EP2903990B1 (en) 2017-06-14
GB201217704D0 (en) 2012-11-14
US20150274748A1 (en) 2015-10-01
RU2015116643A (ru) 2016-11-27
BR112015007503A2 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
IN2015DN03751A (th)
BR112016011484A2 (pt) Derivados de imidazopirimidina como moduladores de atividade de tnf
TN2015000285A1 (en) Therapeutically active pyrazolo-pyrimidine derivatives
WO2013024291A3 (en) Therapeutically active fused pyrimidine derivatives
BR112014008865A2 (pt) imidazo[1,2-c]pirimidinas 5,7-substituídas
UY33865A (es) Derivados Heterocíclicos Novedosos y su Uso en el Tratamiento de Trastornos Neurológicos
BR112016011483A2 (pt) Derivados de imidazotriazina como moduladores de atividade de tnf
IL229193A0 (en) The history of pyridine-2--(h1) and its effectiveness as drugs for the treatment of myeloproliferative disorders, graft rejection, and infectious and immune-mediated diseases
EA201590663A1 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ
CO6440524A2 (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la quinasa janus.
BR112018006135A2 (pt) derivados de pirazol fundidos como inibidores da cinase
EA201690093A1 (ru) Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний
NZ703111A (en) Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
BR112016012243A2 (pt) Derivados de imidazopiridina como moduladores de atividade de tnf
BR112016011485A2 (pt) Derivados de imidazopiridazina como moduladores de atividade de tnf
BR112016011527A2 (pt) Derivados de imidazopiridina como moduladores de atividade de tnf
BR112016012254A2 (pt) Derivados de triazolpiridazina como moduladores de atividade de tnf
HRP20182021T1 (hr) Derivati [1,2,4]triazolo[1,5-a]pirimidina kao inhibitori proteazoma protozoe za liječenje parazitskih bolesti poput lišmenijaze
BR112016029632A2 (pt) derivados heteroaromáticos bicíclicos fundidos como inibidores de cinase
EA201891349A1 (ru) Производные гексагидропиразинотриазинона в качестве ингибиторов киназы
EA201890826A1 (ru) Конденсированные производные пиридина в качестве ингибиторов киназы
UA114825C2 (uk) Терапевтично активні похідні піразолопіримідину
ECSP11011535A (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la quinasa janus